Show simple item record

dc.contributor.authorStone, V. M.
dc.contributor.authorHankaniemi, M. M.
dc.contributor.authorLaitinen, O. H.
dc.contributor.authorSioofy-Khojine, A. B.
dc.contributor.authorLin, A.
dc.contributor.authorDiaz Lozano, I. M.
dc.contributor.authorMazur, M. A.
dc.contributor.authorMarjomäki, V.
dc.contributor.authorLoré, K.
dc.contributor.authorHyöty, H.
dc.contributor.authorHytönen, V. P.
dc.contributor.authorFlodström-Tullberg, M.
dc.date.accessioned2020-05-18T08:42:11Z
dc.date.available2020-05-18T08:42:11Z
dc.date.issued2020
dc.identifier.citationStone, V. M., Hankaniemi, M.M., Laitinen, O. H., Sioofy-Khojine, A. B., Lin, A., Diaz Lozano, I. M., Mazur, M. A., Marjomäki, V., Loré, K., Hyöty, H., Hytönen, V. P., & Flodström-Tullberg, M. (2020). A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. <i>Science Advances</i>, <i>6</i>(19), Article eaaz2433. <a href="https://doi.org/10.1126/sciadv.aaz2433" target="_blank">https://doi.org/10.1126/sciadv.aaz2433</a>
dc.identifier.otherCONVID_35400162
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/69009
dc.description.abstractCoxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor in type 1 diabetes. Vaccines against CVBs are not currently available, and here we describe the generation and preclinical testing of a novel hexavalent vaccine targeting the six known CVB serotypes. We show that the vaccine has an excellent safety profile in murine models and nonhuman primates and that it induces strong neutralizing antibody responses to the six serotypes in both species without an adjuvant. We also demonstrate that the vaccine provides immunity against acute CVB infections in mice, including CVB infections known to cause virus-induced myocarditis. In addition, it blocks CVB-induced diabetes in a genetically permissive mouse model. Our preclinical proof-of-concept studies demonstrate the successful generation of a promising hexavalent CVB vaccine with high immunogenicity capable of preventing CVB-induced diseases.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherAmerican Association for the Advancement of Science
dc.relation.ispartofseriesScience Advances
dc.rightsCC BY-NC 4.0
dc.titleA hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202005183263
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.oppiaineSolu- ja molekyylibiologiafi
dc.contributor.oppiaineNanoscience Centerfi
dc.contributor.oppiaineCell and Molecular Biologyen
dc.contributor.oppiaineNanoscience Centeren
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2375-2548
dc.relation.numberinseries19
dc.relation.volume6
dc.type.versionpublishedVersion
dc.rights.copyright© 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
dc.rights.accesslevelopenAccessfi
dc.subject.ysoimmuniteetti
dc.subject.ysovasta-aineet
dc.subject.ysoenterovirukset
dc.subject.ysonuoruustyypin diabetes
dc.subject.ysokoe-eläinmallit
dc.subject.ysorokotteet
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p7524
jyx.subject.urihttp://www.yso.fi/onto/yso/p12206
jyx.subject.urihttp://www.yso.fi/onto/yso/p20689
jyx.subject.urihttp://www.yso.fi/onto/yso/p19788
jyx.subject.urihttp://www.yso.fi/onto/yso/p28104
jyx.subject.urihttp://www.yso.fi/onto/yso/p15634
dc.rights.urlhttps://creativecommons.org/licenses/by-nc/4.0/
dc.relation.doi10.1126/sciadv.aaz2433
jyx.fundinginformationWe would like to acknowledge the financial support from the Business Finland [formerly TEKES (THERDIAB project, diary no. 1843/31/2014)]; the Academy of Finland (grant nos. 288671 and 1309455); the Swedish Child Diabetes Foundation; and Karolinska Institutet including the Strategic Research Program in Diabetes.
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY-NC 4.0
Except where otherwise noted, this item's license is described as CC BY-NC 4.0